Floatz Rating
C39/100
Confidence
Indicative
Sponsor
Zhejiang University
Modality
Cell therapy
Development Phase
Early Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
24Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05263817CT.gov A Clinical Study of CD19/BCMA CAR-T Cells in the Treatment of Refractory POEMS Syndrome, Amyloidosis, Autoimmune Hemolytic Anemia, and Vasculitis | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Amyloidosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Bcma Car T Cells (this asset) | Zhejiang University | Early P1 | C · 39 |
| Acoramidis | Bayer | P4 | BBB |
| Dexasone | Ascentage Pharma Group Inc. | P3 | BB |
| Empagliflozin | Columbia University | P4 | BB |
| Tafamidis | Pfizer | P4 | BB |
| Lenalidomide | Ascentage Pharma Group Inc. | P3 | BB |
| Cyclophosphamide | University of Alabama at Birmingham | P2 | BB |
| Enavogliflozin | Seoul St. Mary's Hospital | P4 | BB |
| Inotersen | Brigham and Women's Hospital | P3 | BB |
+26 more in the Amyloidosis cohort
Other indications for Bcma Car T Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| POEMS Syndrome | — | Early P1 | C · 39 |
| Autoimmune Hemolytic Anemia | — | Early P1 | C · 39 |
| Vasculitis | — | Early P1 | C · 39 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Bcma Car T Cells in Amyloidosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/bcma-car-t-cells-amyloidosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →